Corbus Pharmaceuticals Holdings, Inc. CRBP
Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) is an oncology drug developer. Its lead program, CRB-701 (SYS6002), is in Phase 2 for Nectin-4-expressing solid tumors (2L oropharyngeal/head and neck SCC, cervical cancer). Its next catalyst on record is CRB-701: Data for CRB-701 plus Keytruda in first-line OPSCC (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CRB-701 — Data for CRB-701 plus Keytruda in first-line OPSCC (Q1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CRB-701 (SYS6002) | Nectin-4 positive solid tumors: HNSCC/OPSCC, cervical cancer, urothelial | antibody | Phase 2 |
| CRB-913 | Obesity | small molecule | Phase 1 |
| CRB-601 | Solid tumors (deprioritized, no further enrollment) | antibody | Phase 1 |
Recent results and decisions
- Oct 15, 2026positive CRB-913 achieved 5.0% placebo-adjusted weight loss at 60 mg dose in 12-week Phase 1b CANYON-1 trial with favorable safety profile and no serious treatment-related adverse events.
5% weight loss at 12 weeks with no evidence of plateauing (comparable to oral GLP-1)
Filing - Sep 14, 2026positive Phase 1b CANYON-1 (primary endpoint safety/tolerability) showed placebo-adjusted weight loss of 2.8%, 3.3% and 5.0% at 20/40/60 mg after 12 weeks (all p<0.0001 vs placebo), with no plateau; generally well tolerated.
The data demonstrated statistically significant and clinically meaningful weight loss at all three doses with the 60 mg dose achieving a mean weight loss of 5% at 12 weeks.
Filing - May 26, 2026positive Phase 1/2 CRB-701 at 3.6 mg/kg: confirmed ORR 42.9% (9/21) in 2L OPSCC, median DOR 6.3 months, PFS 5.6 months.
Confirmed ORR of 42.9% observed in 2L oropharyngeal squamous cell carcinoma (OPSCC) at 3.6 mg/kg with median DOR of 6.3 months and PFS of 5.6 months (ongoing)
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.